Innovative New Medicines are Key to Economic Growth
October 12, 2009 by mdbeckerpartners · 1 Comment
The life sciences industry [herein includes pharmaceutical, biotechnology, diagnostic and medical device companies] plays a critical role in the United States [US] economy. Innovative new medicines developed by life sciences companies provide better patient outcomes, improved quality of care, increased life expectancy, and lead to economic gains.
Currently, the strengths [e.g. innovation, quality of care] and [...]
Bridging the Gap – Translating NIH Funding in a Post-Stimulus Economy
May 22, 2009 by mdbeckerpartners · Leave a Comment
On February 17, 2009, President Obama announced as part of the 2009 stimulus bill, an increase of approximately $10B dollars to the budget for the National Institute of Health (NIH). This is a much needed increase in funding as government sponsored biomedical research has remained relatively flat over the past several years (Figure 1). Whether [...]
Bailout for Banks and Auto Industry…What about Biotechnology?
December 19, 2008 by mdbeckerpartners · Leave a Comment
As the CEO of a few small, publicly-traded biotechnology companies during the past several years, I find the rationale for determining which companies or industries receive government assistance these days to be a highly confusing subject.
Originally it appeared that banks received special attention, until Bear Stearns was deemed too big to fail, while Lehman Brothers [...]
